Content Type: Commentary & Opinion

FDA Approval of Eteplirsen for Muscular Dystrophy (Reply)

March 16, 2026

Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities

March 16, 2026

Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs (Reply)

March 16, 2026

The Evolving Role of Biomarker Patents in Personalized Medicine

March 16, 2026

Applying Academic Detailing and Process Change to Promote Choosing Wisely

March 16, 2026

Eliminating Coverage Discrimination Through the Essential Health Benefit’s Anti-Discrimination Provisions

March 16, 2026

Evidence Required for Drugs Granted Accelerated Approval (Reply)

March 16, 2026

Massachusetts’ Proposed Medicaid Reforms—Cheaper Drugs and Better Coverage?

March 16, 2026

The Backlash Against Bioequivalence and the Interchangeability of Brand-Name and Generic Drugs

March 16, 2026

Permitting Product Liability Litigation for FDA-Approved Drugs and Devices Promotes Patient Safety

March 16, 2026

Priority Review Vouchers: An Inefficient and Dangerous Way to Promote Neglected-Disease Drug Development

March 16, 2026

Drug Company Gifts to Medical Students: The Hidden Curriculum

March 16, 2026